Dr Reddy's Laboratories shares dropped nearly 7% on Friday after the company reported a slight increase in net profit for the ...
Dr Reddy’s Laboratories reports 2% increase in net profit, attributing growth to new acquisitions and product launches.
CEO of Dr Reddy's Laboratories, Erez Israeli believes his company's affordable medicines benefit the U.S. market and will be ...
In early trade, Nifty rose 0.31 per cent to 23,277, while the 30-stock Sensex advanced 0.31 per cent to 76,765. Seven out of the 12 sectors on the NSE advanced, with Nifty Metal and Nifty Oil and gas ...
PayTM(Rs. 673.34 crore), HDFC Bank(Rs. 628.41 crore), Aegis Logistics(Rs. 548.06 crore), Dr. Reddys(Rs. 508.47 crore), Kalyan ...
Dr. Reddy’s Laboratories shares fell by 6.2%, hitting an intraday low of Rs 1,209.70 on the BSE on Friday, January 24, ...
Shares of Dr Reddy's Laboratories Ltd tumbled more than 6.65 per cent to Rs 1,203.60 on Friday, with its total market capitalisation slipping below Rs 1 lakh crore mark.
The company logged a growth of 15.9% in its revenue from operations at ₹8,358.60 Crore versus ₹7,215 Crore in Q3FY24.
Dr. Reddy's Laboratories shares in Friday's trade slipped by over 6 per cent in early trade to the day's low price of Rs 1,203.6 after the pharma major posted weak performance during the December ...
Extending losses for the second session, Dr Reddy’s shares dropped 6.65% to hit a low of ₹1,203.60 on the BSE as investors weighed weak Q3 results.
(Reuters) -Indian shares gave up opening gains to inch lower on Friday, as worries over moderation in corporate earnings ...
Revlimid is a medicine used to treat certain cancers and serious conditions affecting blood cells and bone marrow.